Work

How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons

Year: 2024

Type: article

Abstract: AI techniques are making inroads into the field of drug discovery. As a result, a growing number of drugs and vaccines have been discovered using AI. However, questions remain about the success of these molecules in clinical trials. To address these questions, we conducted a first analysis of the clinical pipelines of AI-native Biotech companies. In Phase I we find AI-discovered molecules have an 80-90% success rate, substantially higher than historic industry averages. This suggests, we argue, that AI is highly capable of designing or identifying molecules with drug-like properties. In Phase II the success rate is ∼40%, albeit on a limited sample size, comparable to historic industry averages. Our findings highlight early signs of the clinical potential of AI-discovered molecules.

Source: Drug Discovery Today

DOI: 10.1016/j.drudis.2024.104009

Authors: Madura KP Jayatunga, Margaret Ayers, Lotte Bruens, Dhruv Jayanth, Christoph Meier

Institution: Boston Consulting Group (United States)

Language: English

Topic: Computational Drug Discovery Methods

Subfield: Drug Discovery

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,820